Sponsors (65)
Official title: To advance research to achieve medical breakthroughs in brain tumor treatment and improve awareness and adequacy of specialized cancer and brain tumor care.
Introduced April 9, 2025 by Brian K. Fitzpatrick · Last progress April 9, 2025
The bill redirects modest-to-significant federal resources to accelerate brain tumor research, trials, and survivorship care—improving access and scientific capacity for affected patients and researchers while raising taxpayer costs, administrative burdens, data‑privacy risks, and the potential to shift research attention away from other priorities.
Patients with glioblastoma and other brain tumors will get substantially expanded, dedicated federal research funding and coordinated programs (including cellular immunotherapy/CAR‑T efforts) that accelerate development of new treatments.
People with brain tumors will have better access to clinical trials and biomarker-driven studies through clearer eligibility guidance, expanded outreach, and programs that reduce unnecessary exclusions, speeding enrollment.
Researchers gain public access to a searchable NIH biospecimen catalog and improved sample‑sharing and reporting, making it easier to find and use tumor samples for research and collaboration.
Taxpayers and the federal budget face increased spending commitments (multiple authorizations totaling tens of millions per year), raising budgetary costs without offsets.
Concentrating new funding and attention on glioblastoma and cellular immunotherapies risks diverting NIH resources and investigator effort away from other cancers and research priorities.
Administrative and compliance burdens (reporting biospecimen collections, applying for pilots/grants) could strain hospitals, academic centers, and smaller providers and risk funding sanctions for reporting violations.
Based on analysis of 12 sections of legislative text.
Authorizes NIH/NCI programs, reporting, pilot grants, and outreach to accelerate brain tumor research, biospecimen transparency, survivorship care, and trial access.
Strengthens federal support for brain tumor research, data sharing, clinical trial access, survivor care, and public education. It requires public reporting of NIH-funded brain tumor biospecimen collections, creates NCI programs to accelerate glioblastoma therapeutics and cellular immunotherapy research, funds pilot programs for survivorship care, directs an HHS awareness campaign on clinical trials and biomarker testing, and asks FDA to issue guidance to reduce trial exclusion of brain tumor patients.